Literature DB >> 1237080

Harringtonine, an inhibitor of initiation of protein biosynthesis.

M T Huang.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1975        PMID： 1237080

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN： 0026-895X            Impact factor:   4.436


× No keyword cloud information.
  48 in total

Review 1.  Promising approaches in acute leukemia.

Authors:  J Cortes; H M Kantarjian
Journal:  Invest New Drugs       Date:  2000-02       Impact factor: 3.850

2.  Eukaryotic protein synthesis inhibitors identified by comparison of cytotoxicity profiles.

Authors:  Jenny Chan; Shakila N Khan; Isabelle Harvey; William Merrick; Jerry Pelletier
Journal:  RNA       Date:  2004-03       Impact factor: 4.942

3.  Reactivation of stalled polyribosomes in synaptic plasticity.

Authors:  Tyson E Graber; Sarah Hébert-Seropian; Arkady Khoutorsky; Alexandre David; Jonathan W Yewdell; Jean-Claude Lacaille; Wayne S Sossin
Journal:  Proc Natl Acad Sci U S A       Date:  2013-09-16       Impact factor: 11.205

4.  Specificity of protein synthesis inhibitors in the inhibition of encephalomyocarditis virus replication.

Authors:  T V Ramabhadran; R E Thach
Journal:  J Virol       Date:  1980-04       Impact factor: 5.103

5.  Cytotoxicity and cell cycle specificity of homoharringtonine.

Authors:  D M Baaske; P Heinstein
Journal:  Antimicrob Agents Chemother       Date:  1977-08       Impact factor: 5.191

6.  Omacetaxine: a protein translation inhibitor for treatment of chronic myelogenous leukemia.

Authors:  Varsha Gandhi; William Plunkett; Jorge E Cortes
Journal:  Clin Cancer Res       Date:  2014-02-05       Impact factor: 12.531

Review 7.  Phenotypic screening in cancer drug discovery - past, present and future.

Authors:  John G Moffat; Joachim Rudolph; David Bailey
Journal:  Nat Rev Drug Discov       Date:  2014-07-18       Impact factor: 84.694

8.  Homoharringtonine: a phase I evaluation.

Authors:  J A Stewart; I H Krakoff
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

9.  Antitumor activity and mechanism of action of the marine compound girodazole.

Authors:  F Lavelle; A Zerial; C Fizames; B Rabault; A Curaudeau
Journal:  Invest New Drugs       Date:  1991-08       Impact factor: 3.850

10.  A phase II open-label study of the intravenous administration of homoharringtonine in the treatment of myelodysplastic syndrome.

Authors:  N Daver; A Vega-Ruiz; H M Kantarjian; Z Estrov; A Ferrajoli; S Kornblau; S Verstovsek; G Garcia-Manero; J E Cortes
Journal:  Eur J Cancer Care (Engl)       Date:  2013-05-23       Impact factor: 2.520
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.